THE TAPE
AKTS · Pharmaceutical Preparations · $863.7M

Aktis Oncology, Inc. Common stock

$16.16▼ −2.77%
Last close
Relative strength
99RS
of 99, against every stock• 0 on the month
Powering up
Unconfirmed
−21.8%
six months against Pharmaceutical Preparations
52-week range
−52.7%
from the high
$0.03$34.19
Setup
falling wedgefresh breakout
+9.8%
against the pivot at $14.71
No report date on the calendar.
No US GAAP filings to read.
11/16 O 16.63 H 17.00 L 16.10 Vol 597.5K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS99
vs pivot+9.84%
Tightening0.94×
Dry-up1.22×
Up/down vol-0.31
From high53%
fresh breakout2 of 9checks
Previous breakout stopped out ▼ −14.74% in Jun
Powering up
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$17.03
+5.4% · tested 3× · last 12 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 12.2 weeks and fell 50% from its ceiling at its deepest. The pivot is $14.71, and the stock closed 9.8% above that pivot. Its relative strength rating is 99.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
+2.7%
Three months against its industry
-25.3%
Six months against its industry
-21.8%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 12.1% either way across its last 4 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-13
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-11-11
+6.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+6.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week lowTape · 2026-11-03
2.6x vol
Mixed: stocks have outrun random stocks by 0.6% over three sessions, not consistently enough to call (746 cases over 51 nights). Against their own sector they have outrun by 0.2%.
GappedTape · 2026-11-03
-8.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-03
4.0 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-10-31
-5.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-24
-6.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?Zacks Investment Research · 6 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
11
$3,231,412 total

Sold: Czibere Akos, Herrmann Ken, Ron-Bigger Shulamit.

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-23 Czibere Akos · Chief Medical Officeroption exercise12,500$61,875
2026-09-23 Czibere Akos · Chief Medical Officersell5,099$102,973
2026-09-23 Czibere Akos · Chief Medical Officersell7,401$155,648
2026-07-20 Herrmann Ken · Directoroption exercise3,506$280
2026-07-20 Herrmann Ken · Directoroption exercise1,350$2,579
2026-07-20 Herrmann Ken · Directorsell3,506$86,115
2026-07-20 Herrmann Ken · Directorsell1,350$33,159
2026-07-17 Herrmann Ken · Directoroption exercise3,065$245

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$14.71
Wrong below$13.71
Measured target · the shape's own height$17.82
Reward against risk3.1×
Lines closed · of the gap they started with3%
Through to the apex48%
Touches · swing points the lines are drawn through10 up · 10 down
Length12.2 weeks
What lines up

2 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy9
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Aktis Oncology, Inc. Common stock (AKTS) — The Tape